Anti-coagulants Market in the US to grow at a CAGR of 6.67% during the period 2016 - 2020; Finds New Report

Report forecast the anti-coagulants market in the US to grow at a CAGR of 6.67% during the period 2016-2020.

Anticoagulants have been used for over 80 years to treat clotting disorders. It is used as a first line of defense for disorders such as deep vein thrombosis (DVT), pulmonary embolism, AF, and acute coronary syndrome. With the advent of time, traditional therapies are replaced by novel oral anticoagulants, which have better safety and efficacy profiles.

The 1990s saw rapid development in the field of direct thrombin inhibitors. Though these drugs, such as hirudin, have been in use from the early 19th century, they were accepted with the development of genetic engineering technology. The recombinant forms, such as desirudin, are also available in the market. During the same period, the focus shifted toward the development of factor Xa inhibitors, and by early 2000s, the first indirect factor Xa inhibitor, fondaparinux, was released into the market. These drugs were administered by parenteral route.

The report covers the present scenario and the growth prospects of the anti-coagulants market in the US for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generics drugs used to treat coagulation disorders. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market.

According to the report, a key growth driver would be the growing prevalence of coagulation disorders. Anticoagulants are prescribed in conditions such as AF, DVT, pulmonary embolism, stroke, clotting disorders, heart attack, and renal diseases. Cardiovascular disorders, kidney disorders, and strokes are becoming more prevalent due to unhealthy lifestyles among individuals, including a lack of physical activity, excessive alcohol consumption, and smoking. It is estimated that 900,000 people are affected each year by DVT or pulmonary embolism, and 60,000-100,000 individuals die of this condition in the US. They are a major cause of maternal and hospital deaths in the US. Heart diseases are the leading cause of death in the region, with an estimated 610,000 deaths reported every year.

Further, the report states that one challenge that could hamper market growth is the side effects associated with drugs.

Anti-Coagulants Market in the US 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

key players in the Anti-Coagulants Market in the US: Johnson & Johnson, Bristol-Myers Squibb, Boehringer Ingelheim, Sanofi, and Daiichi Sankyo.

Other Prominent Vendors in the market are: Armatheon Inc., Aspen, AstraZeneca, Bayer, Cellceutix, Cosmo Pharmaceuticals SA, CSL Behring, Eisai, GSK, Marathon Pharmaceuticals LLC, Ockham Biotech, Perosphere, Portola Pharmaceuticals, Sagent Pharmaceuticals Inc., The Medicines Company, Urigen Pharmaceuticals Inc., and Valeant Pharmaceuticals.

Market driver

• Growing prevalence of coagulation disorders
• For a full, detailed list, view our report

Market challenge

• Side-effects associated with drugs
• For a full, detailed list, view our report

Market trend

• Expected exploitation of new therapeutic use
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Spanning over 89 pages and 56 Exhibit “Anticoagulants Market in the US 2016 - 2020” report covers Executive summary, Scope of the report, Market research methodology, Introduction, Market landscape, Anticoagulants: An overview, Reimbursement scenario, Anticoagulant reversal agents, Approved anticoagulants in US, Anticoagulants pipeline portfolio, Market landscape, Market segmentation by ROA, Market segmentation by drug class, Market segmentation by application, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Appendix.

For more information Visit at: http://mrr.cm/JAz

Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare